Vivacy

Executive Summary

Vivacy is a French medical aesthetics company established in 2007, specializing in the development, manufacturing, and global distribution of premium hyaluronic acid (HA) dermal fillers. Its core product lines, Stylage® and Desirial®, are designed for aesthetic and anti-aging treatments, including wrinkle filling, skin hydration, and facial volumization. The company differentiates itself through advanced HA cross-linking technology that emphasizes safety, natural-looking outcomes, and high patient satisfaction. With a strong presence in Europe and expanding international distribution, Vivacy competes with industry leaders like Galderma and Allergan in the rapidly growing injectable aesthetics market. Vivacy's growth trajectory is supported by increasing demand for non-surgical aesthetic procedures and its reputation for product quality. The company continues to invest in R&D to develop next-generation fillers with improved longevity and biocompatibility. Key upcoming catalysts include potential US FDA approval for Stylage®, which would unlock the world's largest aesthetics market, and the launch of new formulations leveraging innovative cross-linking technologies. Additionally, strategic partnerships in Asia and Latin America could accelerate revenue growth. While private, Vivacy benefits from a strong brand and a loyal practitioner base, positioning it for sustained expansion.

Upcoming Catalysts (preview)

• Q4 2026FDA approval or 510(k) clearance for Stylage® in the US market40% success
• Q3 2026Launch of next-generation HA filler with enhanced cross-linking technology60% success
• Q2 2026Strategic distribution partnership in China or other Asian markets50% success